Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
homoharringtonine + cytarabine + granulocyte colony-stimulating factor + venetoclax + azacitidine
- Development stage
- Unknown
- Lead developer
- Navy General Hospital, Beijing
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
A combination regimen consisting of the CHG regimen (homoharringtonine, cytarabine, and G-CSF) plus venetoclax and azacitidine. It is being investigated for the treatment of newly diagnosed acute myeloid leukemia (AML). Homoharringtonine inhibits protein synthesis; cytarabine is a pyrimidine analog that interferes with DNA synthesis; G-CSF (granulocyte colony-stimulating factor) is used to prime leukemic cells and support neutrophil recovery; venetoclax is a selective BCL-2 inhibitor that induces apoptosis; and azacitidine is a hypomethylating agent that incorporates into DNA and RNA to inhibit methyltransferases. This multi-drug approach targets multiple pathways including apoptosis, DNA methylation, and cytotoxic cell death.
- Other names
- CHG-VACHG regimen combined with venetoclax and azacitidine
02
Targets
BCL-2 (BCL-2 family)CSF3R (Granulocyte colony-stimulating factor receptor)DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNA polymerase family80S A-site (Eukaryotic ribosomal aminoacyl-tRNA site (A-site))NKRF (NF-kappa-B-repressing factor)DNARibosome
Beyond the preview
Go deeper on homoharringtonine + cytarabine + granulocyte colony-stimulating factor + venetoclax + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on homoharringtonine + cytarabine + granulocyte colony-stimulating factor + venetoclax + azacitidine.